The European treatment of severe atopic eczema in children taskforce (TREAT) survey
(2013) In British Journal of Dermatology 169(4). p.901-909- Abstract
- BackgroundThere is a paucity of evidence for the use of systemic agents in children with atopic eczema refractory to conventional therapy, resulting in considerable variation in patient management. ObjectivesThe European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey was established to collect data on current prescribing practice, to identify factors influencing the use of specific systemic agents, and to inform the design of a clinically relevant intervention study. MethodsConsultant physician members of the paediatric dermatology societies and interest groups of eight European countries were invited to participate in a web-based survey. The multiple-response format questionnaire collated data on clinical practice... (More)
- BackgroundThere is a paucity of evidence for the use of systemic agents in children with atopic eczema refractory to conventional therapy, resulting in considerable variation in patient management. ObjectivesThe European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey was established to collect data on current prescribing practice, to identify factors influencing the use of specific systemic agents, and to inform the design of a clinically relevant intervention study. MethodsConsultant physician members of the paediatric dermatology societies and interest groups of eight European countries were invited to participate in a web-based survey. The multiple-response format questionnaire collated data on clinical practice in general, as well as detailed information on the use of systemic agents in refractory paediatric atopic eczema. ResultsIn total, 343/765 members (44.8%) responded to the invitational emails; 89.2% were dermatologists and 71% initiate systemic immunosuppression for children with severe atopic eczema. The first-line drugs of choice were ciclosporin (43.0%), oral corticosteroids (30.7%) and azathioprine (21.7%). Ciclosporin was also the most commonly used second-line medication (33.6%), with methotrexate ranked as most popular third choice (26.2%). Around half of the respondents (53.7%) replied that they routinely test and treat reservoirs of cutaneous infection prior to starting systemic treatment. Across the eight countries, penicillins were the first-line antibiotic of choice (78.3%). ConclusionsIn the absence of a clear evidence base, the European TREAT survey confirms the wide variation in prescribing practice of systemic immunosuppression in refractory paediatric atopic eczema. The results will be used to inform the design of a randomized controlled trial relevant to patient management across Europe. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4163399
- author
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- British Journal of Dermatology
- volume
- 169
- issue
- 4
- pages
- 901 - 909
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000325550200021
- scopus:84885657069
- ISSN
- 1365-2133
- DOI
- 10.1111/bjd.12505
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Department of Dermatology and Venerology (013241320)
- id
- 66e4da20-b7f9-49aa-922f-25a9fd4fe991 (old id 4163399)
- date added to LUP
- 2016-04-01 09:55:13
- date last changed
- 2022-04-19 20:52:55
@article{66e4da20-b7f9-49aa-922f-25a9fd4fe991,
abstract = {{BackgroundThere is a paucity of evidence for the use of systemic agents in children with atopic eczema refractory to conventional therapy, resulting in considerable variation in patient management. ObjectivesThe European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey was established to collect data on current prescribing practice, to identify factors influencing the use of specific systemic agents, and to inform the design of a clinically relevant intervention study. MethodsConsultant physician members of the paediatric dermatology societies and interest groups of eight European countries were invited to participate in a web-based survey. The multiple-response format questionnaire collated data on clinical practice in general, as well as detailed information on the use of systemic agents in refractory paediatric atopic eczema. ResultsIn total, 343/765 members (44.8%) responded to the invitational emails; 89.2% were dermatologists and 71% initiate systemic immunosuppression for children with severe atopic eczema. The first-line drugs of choice were ciclosporin (43.0%), oral corticosteroids (30.7%) and azathioprine (21.7%). Ciclosporin was also the most commonly used second-line medication (33.6%), with methotrexate ranked as most popular third choice (26.2%). Around half of the respondents (53.7%) replied that they routinely test and treat reservoirs of cutaneous infection prior to starting systemic treatment. Across the eight countries, penicillins were the first-line antibiotic of choice (78.3%). ConclusionsIn the absence of a clear evidence base, the European TREAT survey confirms the wide variation in prescribing practice of systemic immunosuppression in refractory paediatric atopic eczema. The results will be used to inform the design of a randomized controlled trial relevant to patient management across Europe.}},
author = {{Proudfoot, L. E. and Powell, A. M. and Ayis, S. and Barbarot, S. and Baselga Torres, E. and Deleuran, M. and Foelster-Holst, R. and Gelmetti, C. and Hernandez-Martin, A. and Middelkamp-Hup, M. A. and Oranje, A. P. and Logan, K. and Perkins, M. and Patrizi, A. and Rovatti, G. and Schofield, O. and Spuls, P. and Svensson, Åke and Vestergaard, C. and Wahlgren, C. -F. and Schmitt, J. and Flohr, C.}},
issn = {{1365-2133}},
language = {{eng}},
number = {{4}},
pages = {{901--909}},
publisher = {{Wiley-Blackwell}},
series = {{British Journal of Dermatology}},
title = {{The European treatment of severe atopic eczema in children taskforce (TREAT) survey}},
url = {{http://dx.doi.org/10.1111/bjd.12505}},
doi = {{10.1111/bjd.12505}},
volume = {{169}},
year = {{2013}},
}